3 ASX Growth Stocks With Strong Balance Sheets Investors May Want to Watch

Central banks are still weighing further tightening as inflation proves stubborn, which keeps pressure on many companies. That backdrop makes earnings growth even more valuable. The Healthy high growth potential screener focuses on stocks where analysts expect strong earnings growth and balance sheets that can better handle higher rates. This article highlights three of the most compelling stocks from that screener to help you focus your research.

The stocks below are only a small sample, with the full screen surfacing 86 more companies that analysts expect to have strong earnings growth and acceptable financial positions, each with its own compelling story. To identify potential ideas that best match your risk profile and time horizon, head straight into the Healthy high growth potential screener

Mesoblast (ASX:MSB)

Mesoblast is a Melbourne based biotech that develops mesenchymal cell therapies such as Remestemcel L for severe inflammatory and cardiovascular diseases. This is the kind of late stage pipeline that fits the Healthy high growth potential theme. The company currently generates about US$65 million in revenue from developing its cell technology platform for commercialization. At a market cap of roughly A$3.1b, Mesoblast is already a sizeable player in the cell therapy space.

Mesoblast may appeal if you want exposure to a company where earnings expectations are tied to a focused set of late stage assets rather than a broad early stage pipeline. Remestemcel L and Ryoncil already have commercial traction in high need areas, and late stage programs in chronic low back pain and heart failure could reshape the earnings profile if regulators and payers stay on side. At the same time, you are dealing with a business that is still loss making, reliant on external funding and heavily exposed to trial and approval outcomes. For investors comfortable with higher risk, that combination of strong earnings forecasts, a sizeable cell therapy platform and real execution risk can be where some of the most interesting opportunities begin.

Mesoblast’s late stage cell therapy story is accelerating. The real debate now is how those earnings forecasts stack up against funding needs and trial risk. Get the fuller picture with the analyst forecasts for Mesoblast

Westgold Resources (ASX:WGX)

Westgold Resources is a Perth based gold producer focused on two main hubs in Western Australia. It fits the Healthy high growth potential theme through ongoing production and expansion projects that can lift earnings. Most revenue comes from the Murchison operations, which generated about A$1.3b, with the Southern Goldfields assets adding roughly A$691 million. At a market cap of about A$6.4b, Westgold Resources is a sizeable pure play on Australian gold with meaningful leverage to its own production growth plans.

Westgold Resources offers a mix of scale, growth projects and financial strength that may appeal to investors looking at gold. Production from Murchison and Southern Goldfields is being backed up by fresh ore reserves at Fletcher and Beta Hunt, and by hub expansions at Meekatharra and Cue that are aimed at higher volumes and lower unit costs. At the same time, earnings rely heavily on ore grades, cost control and effective integration of the Karora assets, while broader adoption of automation and technology is still a work in progress. For investors who want exposure to a growing gold miner with a solid balance sheet and active project pipeline, the key consideration is how confident they are that these projects will translate into the earnings growth analysts are expecting.

Westgold Resources’ growth story is tied to new reserves and expansion projects. The real question is how that flows through to earnings. Get a clearer read on that balance in the analyst forecasts for Westgold Resources

Lynas Rare Earths (ASX:LYC)

Lynas Rare Earths is a Perth based rare earths producer that runs the Mt Weld mine in Western Australia and downstream processing plants in Kalgoorlie and Gebeng in Malaysia. This mining and processing chain supplies rare earth oxides like neodymium and praseodymium that go into magnets for electric vehicles and renewable energy, which is the core link to the Healthy high growth potential theme. The company has a market cap of about A$16.7b, making it one of the larger dedicated rare earths producers globally.

Lynas Rare Earths gives you focused exposure to rare earths that feed directly into electric vehicles and clean energy, backed by an integrated mine to processing setup at Mt Weld and Gebeng. Recent full year numbers, with A$978 million of sales and A$222 million of net income, are used by some investors to support the idea that earnings are moving in the right direction. Some analysts also see potential for further growth and margin expansion if new capacity and any future magnet partnerships perform as expected. The catch is that a lot of optimism is already reflected in a high P/E and in assumptions about government support, rare earth pricing and smooth ramp up of new plants. Anyone considering Lynas needs to weigh that growth story against factors such as concentrated product exposure, regulatory risk in Malaysia and funding needs for ongoing expansion, and decide whether current expectations leave enough room for positive surprises.

Lynas Rare Earths has an earnings story that seems tied to rare earth demand, yet the real swing factor may sit in how future volumes and pricing play out in the analyst forecasts for Lynas Rare Earths.

Seeking Fresh Alternatives Beyond These Picks

Markets move fast and the best setups can shift before they hit the headlines. Scan curated ideas with real momentum while they are still under the radar for now and consider acting while conditions remain favorable.

• Spot cash rich companies before the crowd by running the list of solid balance sheet and fundamentals (20 results), which filters for stronger fundamentals and balance sheets built to handle tougher conditions.
• Explore potential income strength by checking the 6 dividend fortresses, which groups higher yielding stocks where dividends and balance sheet quality are both front and center.
• Track resource producers with real production stories using the 32 elite gold producer stocks and compare established operators that already sit in that focused selection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com